Download PDF
Thromb Haemost 1997; 78(03): 0974-0983
DOI: 10.1055/s-0038-1657671
Review Article
Schattauer GmbH Stuttgart

Coagulation Disorders Caused by Hydroxyethyl Starch

Johannes Treib
1   The Depts. of Neurology, University of the Saarland, Homburg, Germany
,
Anton Haass
1   The Depts. of Neurology, University of the Saarland, Homburg, Germany
,
Gerhard Pindur
2   The Depts. of Hemostasiology and Transfusion Medicine, University of the Saarland, Homburg, Germany
› Author Affiliations
Further Information

Publication History

Received 09 1997

Accepted after resubmission 24 April 1997

Publication Date:
12 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

Initially, hydroxyethyl starch (HES) was only characterized by its in vitro molecular weight (MW). This is not sufficient because HES is degraded in vivo. One relevant parameter that predicts the rate of enzymatic breakdown is the degree of substitution, a measure of the average number of hydroxyethyl groups per glucose unit. The higher this degree of substitution, the slower the break-down. In addition, because the glucose units can be substituted at carbon 2,3 and 6, different substitution patterns are possible. They are classified by their C2/C6 hydroxyethylation ratio. A higher C2/C6 ratio results in less metabolism of the starch in vivo and results in a larger in vivo MW. This in turn affects therapy, because the larger the in vivo MW, the longer is the duration of the volume effect of HES.

Of particular importance is the fact that HES with a high in vivo MW affects factor VIII/von Willebrand factor which can lead to an acquired von Willebrand syndrome. During a 10-day volume therapy with a medium-MW HES 200, a form that is difficult to metabolize, we observed an 80% drop in factor VIII/von Willebrand factor. Therapy with a medium-MW HES 200, a form that is easily degraded, and therapy with a low-MW HES 70 did not result in a relevant decline of factor VIII/von Willebrand factor.

This explains why hemorrhagic complications have been observed repeatedly in the United States after therapy with HES infusions, some of them lethal. In the United States high-MW HES 480 which is difficult to degrade is most frequently used and results in a larger in vivo MW and subsequent decrease in factor VIII/von Willebrand factor levels. In Europe, medium-MW HES 200 that is easily degraded and low-MW HES 70 are preferred. In the future, HES should be characterized by the in vivo, not the in vitro MW.

 

  • References

  • 1 Symington BE. Hetastarch and bleeding complications. Ann Intern Med 1986; 105: 627-628
    PubMedGoogle Scholar
  • 2 Bianchine JR. To the editor. N Engl J Med 1987; 317: 965
    PubMedGoogle Scholar
  • 3 Cully MD, Larson CP, Silverberg GD. Hetastarch coagulopathy in a neurosurgical patient. Anaesthesiology 1987; 66: 707-708
    CrossrefPubMedGoogle Scholar
  • 4 Damon L, Adams M, Strieker RB, Ries C. Intracranial bleeding during treatment with hydroxyethyl starch. N Engl J Med 1987; 317: 964-965
    PubMedGoogle Scholar
  • 5 Sanfelippo MJ, Suberviola PD, Geimer NF. Development of a von Willebrand like syndrome after prolonged use of hydroxyethyl starch. Am J Clin Pathol 1987; 88: 653-655
    CrossrefPubMedGoogle Scholar
  • 6 Abramson N. Plasma Expanders and Bleeding. Ann Intern Med 1988; 108: 307
    PubMedGoogle Scholar
  • 7 Lockwood DNJ, Bullen C, Machin SJ. A severe coagulophathy following volume replacement with hydroxyethylstarch in a Jehovah’s witness. Anaesthesia 1988; 43: 391-393
    CrossrefPubMedGoogle Scholar
  • 8 Chang JC, Gross HM, Jang NS. Disseminated intravascular coagulation due to intravenous administration of hetastarch. Am J Med Sci 1990; 300: 301-303
    CrossrefPubMedGoogle Scholar
  • 9 Penner M, Fingerhut D, Tacke A. Effect of a new 10% hydroxyethyl starch solution HES/270/0.5 on blood coagulation, blood loss and hemodynamics in comparison with 3.5% PPL. Infusionstherapie 1990; 17: 314-318
    PubMedGoogle Scholar
  • 10 Dalrymple HM, Aitchison R, Collins P, Sekhar M, Colvin B. Hydroxyethyl starch induced acquired von Willebrand’s disease. Clin Lab Haematol 1992; 14: 209-211
    PubMedGoogle Scholar
  • 11 Lazarchick J, Conroy JM. The effect of 6% hydroxyethyl starch and desmopressin infusion on von Willebrand factor: ristocetin cofactor activity. Ann Clin Lab Sci 1995; 25: 306-309
    PubMedGoogle Scholar
  • 12 Trumble ER, Muizelaar JP, Myseros JS, Choi SC, Warren BB. Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg 1995; 82: 44-47
    CrossrefPubMedGoogle Scholar
  • 13 van den BrinkWA, van GenderenP, Thijsse WJ, Michiels JJ. Hetastarch Coagulopathy. J Neurosurg 1996; 85: 367
    PubMedGoogle Scholar
  • 14 Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R. Effects of hydroxyethyl starch on blood coagulation, particularly factor VIII. Transfusion 1985; 25: 349-354
    CrossrefPubMedGoogle Scholar
  • 15 Strauss RG, Stansfield C, Henriksen RA, Villhauer PJ. Pentastarch may cause fewer effects on coagulation than hetastarch. Transfusion 1988; 28: 257-260
    CrossrefPubMedGoogle Scholar
  • 16 Mishler JM. Pharmakokinetik mittelmolekularer Hydroxyathylstarke (HAS 200/0,5). Infusionstherapie 1980; 07: 096-102
    PubMedGoogle Scholar
  • 17 Kohler H, Zschiedrich H, Clasen R, Linfante A, Gamm H. Blutvolumen, kolloidosmotischer Druck und Nierenfunktion von Probanden nach Infusion von mittelmolekularer 10% Hydroxyathylstarke 200/0,5 und 10% Dextran 40. Anaesthesist 1982; 31: 61-67
    PubMedGoogle Scholar
  • 18 Haass A, Kroemer H, Jager H, Oest A, Heinrich B. Hemodilution therapy in cerebral ischemia, different dose and time dependent hemorheological effects of plasma expanders. In: Pharmacology of cerebral ischemia. Kriegel-stein J. ed. Elsevier; Amsterdam: 1986
    Google Scholar
  • 19 Haass A, Stoll M, Treib J. Hemodilution in cerebral circulatory disturbances: Indications, implementation, additional drug treatment and alternatives. In: Hemodilution. New aspects in the management of circulatory blood flow. Improvement of macroand microcirculation. Koscielny J, Kiesewetter H, Jung F, Haass A. eds. Springer, Berlin – Heidelberg – New York: 1992. pp 053-114
    CrossrefGoogle Scholar
  • 20 Kroemer H, Haass A, Müller K, Jäger H, Wagner EM, Heimburg P, Klotz U. Haemodilution therapy in ischaemic stroke: plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0,5. Eur J Clin Pharmacol 1987; 31: 705-710
    CrossrefPubMedGoogle Scholar
  • 21 Karlson KE, Garzon AA, Shaftan GW, Chu C-J. Increased blood loss associated with administration of certain plasma expanders: Dextran 75, dextran 40 and hydroxyethyl starch. Surgery 1967; 62: 670-678
    PubMedGoogle Scholar
  • 22 Landgraf H, Ehrly AM, Saeger-Lorenz K, Vogel C. Untersuchung über den EinfluB einer Infusion von mittelmolekularer Hydroxyäthylstärke (HES-steril 10%) auf die FlieBeigenschaften des Blutes gesunder Probanden. Infusionstherapie 1981; 04: 200-204
    PubMedGoogle Scholar
  • 23 Ehrly AM, Seebens H, Saeger-Lorenz K. EinfluB einer 10%igen und 6%igen Hydroxyäthylstärkelösung (MG 200000/0,62) im Vergleich mit einer 10%igen Dextranlösung (MG 40000) auf die FlieBeigenschaften des Blutes und den Gewebesauerstoffdruck von Patienten mit Claudicatio intermittens. Infusionstherapie 1988; 15: 181-187
    PubMedGoogle Scholar
  • 24 Kiesewetter H, Jung F, Blume J, Bulling B, Franke RP. Vergleichende Untersuchung von niedermolekularen Dextranoder Hydroxyäthylstärkelӧsungen als Volumenersatzmittel bei Hämodilutionstherapie. Klin Wschr 1986; 64: 29-37
    CrossrefPubMedGoogle Scholar
  • 25 Scheffler P, Jung F, Mrowietz C, Waldhausen P, Leipnitz G, Häuser B. Hämorheologische, mikround makrozirkulatorische Effekte einer hypervolämischen Infusion mittelmolekularer Hydroxyäthylstärke (10%, 200000/0,62) bei Gesunden. Infusionstherapie 1987; 14: 233-238
    PubMedGoogle Scholar
  • 26 Jung F, Waldhausen P, Spitzer S, Mrowietz C, Hauser B, Wenzel E. Hämorheologische, mikround makrozirkulatorische Effekte einer hypervolämischen Hämodilution mit mittelmolekularer Hydroxyäthylstärke (HES 200/0,62; 6%). Infusionstherapie 1988; 15: 266-271
    PubMedGoogle Scholar
  • 27 Jung F, Koscielny J, Kolepke W, Scheffler P, Kiesewetter H, Wenzel E. EinfluB einer isobzw. hypervolämischen Hämodilution auf die FlieBfähigkeit des Blutes, die Sauerstofftransportkapazität in der Makround Mikrostrombahn sowie die Gewebesauerstoffversorgung von Hautund Skelettmuskel. In: Hydroxyäthylstärke – eine aktuelle Übersicht. Lawin P. ed. Thieme, Stuttgart; New York: 1989. pp 091-115
    Google Scholar
  • 28 London MJ, Ho JS, Triedman JK, Verrier ED, Levine J, Merrick SH, Hanley FL, Browner WS, Mangono DT. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 1989; 97: 785-797
    PubMedGoogle Scholar
  • 29 Shoemaker WC, Kram HB. Effects of crystalloids and colloids on hemodynamics, oxygen transport and outcome in high-risk surgical patients. in: Simmons RC, Udekuo AS. (eds). Debates in clinical surgery. Yearbook; Chicago: 1990: 263-316
    Google Scholar
  • 30 Kiesewetter H, Jung F, Blume J, Gerhards M. Hämodilution bei Patienten mit peripherer arterieller VerschluBkrankheit im Stadium lib: Prospektiver randomisierter Doppelblind-Vergleich von mittelmolekularer Hydroxyäthylstärke und kleinmolekularer Dextranlӧsung. Klin Wschr 1987; 65: 324-330
    CrossrefPubMedGoogle Scholar
  • 31 Haass A, Stoll M, Treib J. Hämodilution bei cerebralen Durchblutungsstorungen. Indikation, Durchführung, medikamentӧse Zusatzbehandlung und Altemativen. In: Hämodilution, neue Aspekte in der Behandlung von Durchblutungsstӧrungen. Koscielny J, Kiesewetter H, Jung F, Haass A. eds. Springer, Berlin; Heidelberg: 1991. pp 070-145
    Google Scholar
  • 32 Remky A, Wolf S, Hamid M, Bertram B, Schulte K, Arend O, Reim M. EinfluB der Hämodilution -auf die retinale Hämodynamik bei Venenastverschlussen. Ophthalmologe 1994; 91: 288-292
    PubMedGoogle Scholar
  • 33 Hansen D, Hannemann L, Specht M, Schaffartzik W. Zerebraler Vasospasmus nach aneurysmatischer Subarachnoidalblutung. Therapeutischer Stellenwert von Kalzium-Antagonisten, hypervolamischer Hamodilution und induzierter arterieller Hypertension. Anaesthesist 1995; 44: 219-229
    CrossrefPubMedGoogle Scholar
  • 34 Koscielny J, Forster H, Kolepke W, Jung F. Vergleich von isound hypervolämischer Hamodilution mit HES. In: Hämodilution, neue Aspekte in der Behandlung von Durchblutungsstӧrungen. Koscielny J, Kiesewetter H, Jung F, Haass A. eds. Springer, Berlin – Heidelberg – New Nork: 1991. pp 146-228
    Google Scholar
  • 35 Molendijk L, Malburg I, Kopecky P. Dopplersonographische Untersuchungen bei Plazentainsuffizienz als Hinweis auf die Effektivität der Hamodilutionstherapie. Z Geburtshilfe Perinatol 1995; 199: 18-22
    PubMedGoogle Scholar
  • 36 Bsteh M, Tews G, John D. Hämodilution bei der Behandlung der intrauterinen Dystrophie. Geburtsh Frauenheilk 1995; 55: 83-86
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH. Effects of pentastarch and albumin infusion on cardiorespiratory function and cogulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 1989; 17: 394-398
    CrossrefPubMedGoogle Scholar
  • 38 Camu F, Ivens D, Christiaens F. Human albumine and colloid fluid replacement: their use in general surgery. Acta Anaesthesiol Belg 1995; 46: 03-18
    PubMedGoogle Scholar
  • 39 Hankeln K, Senker R, Beez M. Comparative study of the intraoperative efficacy of 5% human albumin and 10% hydroxyethyl starch (HES-steril) in terms of hemodynamics and oxygen transport in 40 patients. Infusionsther Transfusionsmed 1990; 17: 135-140
    PubMedGoogle Scholar
  • 40 Beards SC, Watt T, Edwards JD, Nightingale P, Farragher B. Comparison of the hemodynamic and oxygen transport responses to modified fluid gelatin and hetastarch in critically ill patients. A prospective, randomized trial. Crit Care Med 1994; 22: 600-605
    CrossrefPubMedGoogle Scholar
  • 41 Staedt U. Hämorheologische, makround mikrozirkulatorische Parameter einschliefilich ihrer Interaktionen bei Patienten mit akutem Himinfarkt unter pathophysiologischen und therapeutischen Gesichtspunkten. Habilitationsschrift Heidelberg. 1994
    PubMedGoogle Scholar
  • 42 Baron J-F. Low molecular weight hydroxyethyl starches. In: Plasma volume expansion. Baron J-F. ed. Amette Blackwell; Paris: 1992. pp 121-132
    Google Scholar
  • 43 Yoshida M, Kishikawa T. A study of hydroxyethyl starch. Part II. Degradation-sites of hydroxyethyl starch by pig pankreas alpha-amylase. Starch/ Starke 1984; 36: 167-169
    CrossrefPubMedGoogle Scholar
  • 44 Yoshida M, Minami Y, Kishikawa T. A study of hydroxyethyl starch. Part III. Comparison of metabolic fates between 2-0 hydroxyethyl starch and 6-0-hydroxyethyl starch in rabbits. Starch/Starke 1984; 36: 209-212
    CrossrefPubMedGoogle Scholar
  • 45 Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT, Jung F, Wenzel E, Schimrigk K. HES 200/0,5 is not HES 200/0,5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 1452-1456
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Treib J, Haass A, Pindur G, Grauer MT, Seyfert UT, Treib W, Wenzel E, Schimrigk K. Influence of low molecular weight hydroxyethyl starch on hemostasis and hemorheology. Haemostasis 1996; 26: 258-265
    PubMedGoogle Scholar
  • 47 Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K. All medium starches are not the same. Influence of degree of substitution of hydroxyethyl starch on plasma volume, hemorheologic conditions, and coagulation. Transfusion 1996; 36: 450-455
    CrossrefPubMedGoogle Scholar
  • 48 Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K. Influence of low and medium molecular weight hydroxyethyl starch on platelets during a long-term hemodilution. Arzneim Forsch/Drug Res 1996; 46: 1064-1066
    PubMedGoogle Scholar
  • 49 Messmer K, Jesch F. Volumenersatz und Hämodilution durch Hydroxyäthylstärke. Infusionstherapie 1978; 05: 169-177
    PubMedGoogle Scholar
  • 50 Peter K, Gander HP, Lutz H, Nold W, Strosiek U. Die Beeinflussung der Blutgerinnung durch Hydroxyäthylstärke. Anaesthesist 1975; 24: 219-224
    PubMedGoogle Scholar
  • 51 Vinazzer H, Bergmann H. Zur Beeinflussung postoperativer Änderungen der Blutgerinnung durch Hydroxyäthylstärke. Anaesthesist 1975; 24: 517-520
    PubMedGoogle Scholar
  • 52 Probst W. Elohäst (Hydroxyethylstärke 6% 200/0.60-0.66) bei akuten ischämischen cerebralen Durchblutungsstӧrungen. Elohäst Workshop 1988; 11-12
    PubMedGoogle Scholar
  • 53 Reiger I. Erfahrungen mit Elohäst (Hydroxyethylstärke 6% 200/0.60-0.66) in der Therapie des Cerebralinsults. Elohäst Workshop 1988; 10
    PubMedGoogle Scholar
  • 54 Popov-Cenic S, Müller N, Kladetzky R-G, Hack G, Lang U, Safer A, Rahlfs VW. Durch Prämedikation, Narkose und Operation bedingte Änderungen des Gerinnungsund Fibrinolysesystems und der Thrombozyten. EinfluB von Dextran und Hydroxyäthylstärke (HÄS) während und nach Operation. Anaesthesist 1977; 26: 77-84
    PubMedGoogle Scholar
  • 55 Költringer P, Pfeiffer KP, Lind P, Wakonig P, Langsteger W, Eber O, Reisecker F. Hämodilution mit mittelmolekularer Hydroxyäthylstärke – 6% HÄS 200000/0,60-0,66 – bei Patienten mit peripherer arterieller VerschluBkrankheit. Osterreichische Krankenhauspharmazie 1989; 03: 07-12
    PubMedGoogle Scholar
  • 56 Krentzlin M, Sens B, Barthels M. Subnormale Ristocetin Cofaktor-Werte (VIIIR:RCF) und Blutungsbereitschaft. In: 16. Hämophilie Symposion, Hamburg. Landbeck G. ed. Springer, Berlin – Heidelberg; New York: 1985. pp 207-209
    Google Scholar
  • 57 Budde U, Steinberg A. Analyse der Multimere und Polypeptide des vonWillebrand-Faktors. In: 16. Hämophilie Symposion, Hamburg. Landbeck G. ed. Springer, Berlin – Heidelberg; New York: 1985. pp 179-183
    Google Scholar
  • 58 Batlle J, Del RioF, Fernandez MF, Martin R, Borrasca A. Effect of dextran on factor VUI/von Willebrand factor structure and function. Thromb Haemost 1985; 54: 697-699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Siostrzonek P, Niessner H, Deutsch E, Lechner K, Kominger C, Pabinger I, Heinz R. Vier Fälle mit erworbenem von-Willebrand-Syndrom und monoklonaler Gammopathie. Langzeitverlauf sowie diagnostische und therapeutische Problematik. In: 16. Hämophilie Symposion, Hamburg. Landbeck G. ed. Springer, Berlin – Heidelberg; New York: 1985. pp 248-256
    Google Scholar
  • 60 Ruggeri ZM. Pathogenesis and classification of von Willebrand disease. Haemostasis 1994; 24: 265-275
    PubMedGoogle Scholar
  • 61 Arkel YS, Lynch J, Kamiyama M. Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin. Thromb Haemost 1994; 72: 643-651
    Article in Thieme ConnectPubMedGoogle Scholar
  • 62 Zimmerman TS, Ruggeri ZM. Von Willebrand’s Disease. Clin Haematol 1983; 12: 175-200
    PubMedGoogle Scholar
  • 63 Treib J, Haass A, Pindur G, Miyachita C, Grauer MT, Jung F, Wenzel E, Schimrigk K. Highly substituted hydroxyethyl starch (HES 200/0.62) leads to a type I von Willebrand syndrome after repeated administration. Haemostasis 1996; 26: 210-213
    PubMedGoogle Scholar
  • 64 Conroy JM, Fishman RL, Reeves ST, Pinosky ML, Lazarchick J. The effects of desmopressin and 6% hydroxyethyl starch on factor VIII:C. Anesth Analg 1996; 83: 804-807
    CrossrefPubMedGoogle Scholar
  • 65 Treib W. Beeinflussung von Hämorheologie und Gerinnungssystem durch 10% Hydroxyethylstärke (HES) 200/0,5 und 6% 40/0,50-0,55 im Verlauf einer Langzeithämodilutionsbehandlung. Dissertationsschrift, Homburg 1993; 001-187
    PubMedGoogle Scholar
  • 66 Treib J, Haass A, Pindur G. Hetastarch coagulopathy. J Neurosurg 1996; 85: 367-368
    PubMedGoogle Scholar
  • 67 Treib J, Haass A, Pindur G, Grauer MT, Treib W, Wenzel E, Schimrigk K. Increased hemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch. Arzneim Forsch/Drug Res 1997; 47: 18-22
    PubMedGoogle Scholar
  • 68 Treib J, Haass A. Hydroxyethyl starch. J Neurosurg 1997; 86: 574-575
    PubMedGoogle Scholar
  • 69 Barthels M, Poliwoda H. (Hrsg). Gerinnungsanalysen. Thieme, Stuttgart. 1987
    Google Scholar
  • 70 Blanke H, Praetorius G, Leschke M, Seitz R, Egbring R, Strauer BE. Die Bedeutung des Thrombin-Antithrombin III-Komplexes in der Diagnostik der Lungenembolie und der tiefen Venenthrombose. Klin Wschr 1987; 65: 757-763
    CrossrefPubMedGoogle Scholar
  • 71 Treib J. EinfluB einer 0,62 substituierten Hydroxyäthylstärke 200 auf Hämorheologie und Gerinnungssystem im Verlauf einer Langzeithamodilutionstherapie. Dissertationsschrift, Homburg 1991; 001-200
    PubMedGoogle Scholar
  • 72 Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K. Influence on intravascular molecular weight of hydroxyethyl starch on platelets during a long-term hemodilution. Eur J Hematol 1996; 56: 168-172
    PubMedGoogle Scholar
  • 73 Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K. Abnahme des Thrombozytenvolumens durch mehrtägige Infusion von hochsubstituierter mittelmolekularer Hydroxyäthylstärke (HES 200/0,62). Wien Klin Wochenschr 1996; 108: 20-23
    PubMedGoogle Scholar
  • 74 Kemona H, Andrzejewska A, Prokopowicz J, Nowak H, Mantur M. Phagocytic activity of human blood platelets examined by electron microscopy. Folia Haematol 1986; 113: 696-702
    PubMedGoogle Scholar
  • 75 Levin J, Bessman JD. The inverse relation between platelet volume and platelet number. J Lab Clin Med 1983; 101: 295-307
    PubMedGoogle Scholar
  • 76 Bessman JD, Gilmer PR, Gardner FH. Use of mean platelet volume improves detection of platelet disorders. Blood cells 1985; 11: 127-135
    PubMedGoogle Scholar
  • 77 Erne P, Wardle J, Sanders K, Lewis SM, Maseri A. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost 1988; 59: 259-263
    Article in Thieme ConnectPubMedGoogle Scholar
  • 78 Kristensen SD, Milner PC, Martin JF. Bleeding time and platelet volume in acute myocardial infarction. A 2 year follow-up study. Thromb Haemost 1988; 59: 353-356
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Threatte GA. Usefulness of the mean platelet volume. Clin Lab Med 1993; 13: 937-950
    CrossrefPubMedGoogle Scholar
  • 80 Karpatkin S. Heterogeneity of human platelets, correlation of platelet function with platelet volume. Blood 1978; 51: 307-316
    PubMedGoogle Scholar
  • 81 Eldor A, Avitzour M, Or R, Hanna R, Penchas S. Prediction of haemorrhagic diathesis in thrombocytopenia by mean platelet volume. Brit Med J 1982; 285: 397-400
    CrossrefPubMedGoogle Scholar
  • 82 Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 1982; 50: 509-519
    CrossrefPubMedGoogle Scholar
  • 83 Harke H, Thoenies R, Margraf I, Momsen W. Der EinfluB verschiedener Plasmaersatzmittel auf Gerinnungssystem und Thrombozytenfunktion während und nach operativen Eingriffen. Anaesthesist 1976; 25: 366-373
    PubMedGoogle Scholar
  • 84 Harke H, Pieper C, Meredig J, Rahman S, Rüssler P. Rheologische und gerinnungs-physiologische Untersuchungen nach Infusion von HAS 200/0,5 und Dextran 40. Anaesthesist 1980; 29: 71-77
    PubMedGoogle Scholar
  • 85 Haass A, Kroemer H, Jäger H, Müller K, Decker I, Wagner EM, Schimrigk K. Dextran 40 oder HES 200/0,5 ? Hämorheologie der Langzeitbehandlung beim ischämischen zerebralen Insult. Dtsch Med Wschr 1986; 111: 1681-1686
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Bold J, Müller M, Heesen M, Heyn O, Hempelmann G. Influence of different volume therapies on platelet function in the critically ill. Intens Care Med 1996; 22: 1075-1081
    CrossrefPubMedGoogle Scholar